Search Results

Lexaria Bioscience Corp. which will evaluate various DehydraTECH-GLP-1 formulations and other treatments with efficacy objectives of weight loss, blood sugar reduction, and more.

Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.”

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces it has hired a contract research organization to perform the Company’s human pilot study #3, which will evaluate a dual action GLP-1 + GIP.

Lexaria Bioscience Corp. announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately.

Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 60+ brands within the Dynamic Brand Portfolio @ IBN a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

NetworkNewsAudio – Lexaria Bioscience Corp. announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Even Better?”.

Lexaria Bioscience Corp. announces it has hired a contract research organization to perform the Company’s second DehydraTECH-powered glucagon-like peptide 1 human pilot study #2 (the “Study”).

Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 60+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the “Company” or “Lexaria”) announces that, on January 29, it submitted its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its planned U.S. phase 1b hypertension clinical trial HYPER-H23-1 of DehydraTECH-CBD.